Loading...
•
Dec 31, 2023
Immunocore Q4 2023 Earnings Report
Immunocore reported Q4 2023 financial results, highlighted by KIMMTRAK net revenues of $67.6 million and progress in clinical trials and collaborations.
Key Takeaways
Immunocore reported Q4 2023 financial results with KIMMTRAK net revenues reaching $67.6 million and a net loss of $19.7 million. The company is advancing its clinical trials, including a collaboration with Bristol Myers Squibb. Cash and cash equivalents stood at $442.6 million as of December 31, 2023, with additional funds raised in February 2024.
KIMMTRAK net revenues reached $67.6 million in Q4 2023 and $238.7 million for the full year 2023.
Clinical trial collaboration and supply agreement established with Bristol Myers Squibb for IMC-F106C with nivolumab.
Multiple clinical readouts for IMC-F106C from Phase 1/2 trial expected to start in Q2 2024.
Cash and cash equivalents totaled $442.6 million as of December 31, 2023, with $389.3 million net proceeds from a February 2024 Convertible Senior Notes offering.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Immunocore is focused on expanding the reach of KIMMTRAK, advancing its PRAME ImmTAC therapy, and progressing its clinical candidates across oncology, infectious diseases, and autoimmune diseases.
Positive Outlook
- Maximizing the potential of KIMMTRAK.
- Launching PRAME ImmTAC therapy.
- Advancing clinical candidates across oncology.
- Expanding into infectious diseases.
- Entering autoimmune diseases.
Challenges Ahead
- Impact of worsening macroeconomic conditions.
- Ability to obtain clinical and commercial supply.
- Obtaining and maintaining regulatory approval.
- Competition with respect to market opportunities.
- Unexpected safety or efficacy data.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...